Moderna (MRNA) and Merck (MRK) announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Keytruda, Merck’s anti-PD-1 therapy, demonstrated a "statistically significant and clinically meaningful" improvement in the primary endpoint of recurrence-free survival, or RFS, versus Keytruda alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with Keytruda reduced the risk of recurrence or death by 44% compared with Keytruda alone. Adverse events observed with mRNA-4157/V940 in KEYNOTE-942 were consistent with those previously reported in a Phase 1 clinical trial. The safety profile of KEYTRUDA was consistent with that observed in previously reported studies. Serious treatment-related adverse events occurred in 14.4% of patients who received the combination arm of mRNA-4157/V940 and KEYTRUDA versus 10% with KEYTRUDA alone. The companies plan to discuss the results with regulatory authorities and initiate a Phase 3 study in melanoma patients in 2023. In October of this year, the companies announced that Merck had exercised its option to jointly develop and commercialize mRNA-4157/V940. Merck and Moderna will share costs and any profits equally under this worldwide collaboration. "Today’s results are highly encouraging for the field of cancer treatment. mRNA has been transformative for COVID-19, and now, for the first time ever, we have demonstrated the potential for mRNA to have an impact on outcomes in a randomized clinical trial in melanoma. We will begin additional studies in melanoma and other forms of cancer with the goal of bringing truly individualized cancer treatments to patients. We look forward to publishing the full data set and sharing the results at an upcoming oncology medical conference, as well as with health authorities," said Stephane Bancel, Moderna’s CEO.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- Moderna Soars after Combo Therapy Shows Promise in Melanoma
- Moderna receives FDA EUA for COVID booster in children 6 months-5 years of age
- Moderna appoints Brad Miller Chief Information Officer
- Pfizer dismisses Moderna claim it copied COVID-19 shot, CNBC reports
- Moderna call volume above normal and directionally bullish
Questions or Comments about the article? Write to editor@tipranks.com